Open Access

Two novel susceptibility loci for non‑small cell lung cancer map to low‑density lipoprotein receptor‑related protein 5

  • Authors:
    • Ying Wang
    • Yongjun Zhang
    • Meiyu Fang
    • Wenglong Bao
    • Dehou Deng
  • View Affiliations

  • Published online on: August 5, 2016     https://doi.org/10.3892/ol.2016.4954
  • Pages: 2307-2318
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study investigated the effect of single‑nucleotide polymorphisms (SNPs) of low‑density lipoprotein receptor‑related protein 5 (LRP5) on the risk of developing non‑small cell lung cancer (NSCLC). A total of 500 NSCLC patients and 500 healthy controls were recruited for genotyping of 11 SNPs of LRP5. The association between genotype and NSCLC risk was evaluated by computing the odds ratio (OR) and 95% confidence interval (CI) from multivariate unconditional logistic regression analyses. Eleven Tag SNPs were detected. The frequency of the LRP5 rs3736228 T allele (18.9% in male NSCLC cases and 23.9% in male controls) was statistically different between male NSCLCs and male controls (P=0.03), and the T allele was associated with a lower risk of NSCLC (OR=0.74; 95% CI, 0.56‑0.67), whereas the C/C homozygous genotype and the LRP5 rs64843 T/T genotype were associated with an increased risk of NSCLC and squamous cell carcinoma (SCC), respectively (OR=1.43 and 1.77, respectively). Using Haploview software, the frequency of the haplotypes of rs312009/rs3120015/rs3120014 CCC was was significantly higher in female SCC cases compared with female controls (0.064 vs. 0.009, P=0.04). LRP5 rs3736228 and rs64843 SNPs were significantly associated with an increased risk of NSCLC and SCC, respectively. Further studies are required to investigate the functional changes in LRP5 expression and activity in NSCLC in vitro.

Introduction

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related mortality worldwide. In 2008, lung cancer accounted for 1.6 million of new cases and 1.4 million cancer-related mortalities worldwide (1). Non-small cell lung cancer (NSCLC) is the most common histological subtype, accounting for ~85% of all lung cancers (2). NSCLC is also one of the few cancers for which there has been no substantial progress in early detection and treatment options (3). Tobacco smoke is the single most significant risk factor for lung cancer, and outdoor air pollution (4) and genetic factors are also notable factors (57). A previous study demonstrated that a heritable component or a gene-environment interaction leads to lung cancer development (5); for example, not all tobacco smokers suffer from lung cancer. Thus, it is crucial to identify these genes and their genetic variations to clarify their association with lung cancer risk (6,7).

Low-density lipoprotein-related receptor 5 (LRP5) is a member of the family of lipoprotein receptor-related proteins (LRPs), a small group of single-pass transmembrane proteins (8). LRP5 was originally identified based on its homology to the low-density lipoprotein (LDL) receptor (9); it contains large extracellular domains, including four β-propeller motifs followed by three type 1 LDL ligand-binding domains (10), and is a transmembrane cell-surface receptor involved in receptor-mediated endocytosis of lipoprotein and protein ligands (11). Functionally, LRP5 plays a significant role in Wnt/β-catenin signaling, and the latter is integral to developmental biology. For example, when Wnt ligands bind to a member of the Frizzled family and LRP5, it allows β-catenin to shuttle into the nucleus and bind to T-cell factor/lymphocyte-enhancing factor proteins to activate the canonical Wnt/β-catenin signaling cascade (10). In the absence of the Wnt ligand binding to Frizzled receptors, the canonical Wnt pathway is turned off, which leads to β-catenin degradation. The non-canonical pathway may lead to proliferation of lung cancer cells (12). Signaling by the Wnt family of secreted glycolipoproteins is known to play a key role in the embryonic development of organisms ranging from nematodes to mammals, and is also implicated in several types of human cancer (1315). In lung cancer, it has been reported that lipoprotein receptor-related protein is inactivated in more than 40% of cases (16). Another study has demonstrated that chromosome 11q is frequently altered in NSCLC (17), where LRP5 is localized. Thus, in this study, we hypothesized that LRP5 polymorphisms may play a role in susceptibility to NSCLC.

Patients and methods

Study population

A total of 500 NSCLC patients and 500 unrelated healthy controls were recruited from Zhejiang Cancer Hospital, Hangzhou, China, between March 2011 and April 2012. All cases and controls were of Chinese Han origin and lived in the same geographic region (Zhejiang province, China). Exclusion criteria included a history of previous primary cancer other than lung cancer. The controls were free of lung-related disease to avoid any probable interference from overlapping genes. The control subjects were matched to patients for gender and age. A regular smoker was defined as someone who had smoked more than one pack per year, and a current smoker or former smoker was defined as a regular smoker who still smoked in the year of the interview or in the previous year (18). This study was approved by the Ethics Committee of Zhejiang Cancer Hospital, and all of the studied subjects provided informed consent.

SNP selection and genotyping

Tagging SNPs of LRP5 were selected based on pairwise r2 values (≥0.8) among all common SNPs with a minor allele frequency (MAF) ≥0.1 using the Tagger program implemented in Haploview version 4.1 (http://www.broad.mit.edu/mpg/haploview). The Chinese HapMap database [population=Han Chinese, Beijing (CHB)] was used to select LRP5 SNPs in this study (http://www.hapmap.org).

For the genotyping of LRP5 SNPs, genomic DNA was extracted from whole blood using the AxyPrep Blood Genomic DNA Miniprep kit (Axygen Biosciences, Union City, CA, USA) and subjected to genotyping of LRP5 SNPs with the Sequenom MassARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry platform (Sequenom, San Diego, CA, USA). Primers for polymerase chain reaction (PCR) and single base extension were designed using Assay Designer software version 3.0 (Sequenom) and synthesized by Sangon Biotech (Shanghai, China; Table I).

Table I.

Polymerase chain reaction primers and extensions used in the genotyping of LRP5 single-nucleotide polymorphisms.

Table I.

Polymerase chain reaction primers and extensions used in the genotyping of LRP5 single-nucleotide polymorphisms.

SNPPrimersSequences
Rs49305731 5′-ACGTTGGATGTGTTTCCTGAACGAGCCTGC-3′
2 5′-ACGTTGGATGTGGATGCGCCAGTGTTCCT-3′
Extension 5′-CTTTCCTGCTGTGGACC-3′
Rs3120091 5′-ACGTTGGATGTCTTGGACTCAAGTGGATGG-3′
2 5′-ACGTTGGATGATGTGTCCTCTATGACAGGC-3′
Extension 5′-TTCCCCTTTGTTCCTGTGGC-3′
Rs3120141 5′ACGTTGGATGTAGGGAACGGATAGGACCAG-3
2 5′-ACGTTGGATGTCTGAGCTCTGTGCTGGTTG-3′
Extension 5′-CCTGGAGCCCTGAGTTA-3′
Rs37815901 5′-ACGTTGGATGACATGGGCCTTGCCAAAAAC-3′
2 5′-ACGTTGGATGACGCCCTTCCCACGAAAAC-3′
Extension 5′-GAGGGAGGTGTGGCCATTTCCTGCT-3′
Rs3120151 5′-ACGTTGGATGCTTGTGGATCACAACCAGAC-3′
2 5′-ACGTTGGATGTGTCCTGCGAGAGGCCCTTA-3′
Extension 5′-AGATGCCCTTAGAGGCCAGATCATG-3′
Rs4913471 5′-ACGTTGGATGGTTCTGATGATCCATGAGCC-3′
2 5′-ACGTTGGATGCTCTTTCATCCTGTCCTGAG-3′
Extension 5′-CTGATAGCCGGAGAACTTGGATGTTGC-3′
Rs17842351 5′-ACGTTGGATGTAATGAACCTGTTGTGCCCC-3′
2 5′-ACGTTGGATGCTGTTCCACAAATGATGTGC-3′
Extension 5′-TTTTATGATGTGCTCACGG-3′
Rs6484381 5′-ACGTTGGATGTAACACTTATCGTCGTAACC-3′
2 5′-ACGTTGGATGTGGCAGTGGTTACCAGCAAC-3′
Extension 5′-ATTTTCTTAATGCCACTGAACTTCAC-3′
Rs37362281 5′-ACGTTGGATGTCTTGGCAGAGCCTTGACG-3′
2 5′-ACGTTGGATGAGACTGTCAGGACCGCTCA-3′
Extension 5′-GGGAGACCGCTCAGACGAGG-3′
Rs6249471 5′-ACGTTGGATGTGAAAGCCAGCTGGGTGTAG-3′
2 5′-ACGTTGGATGAACGCTGCTCCCTGTCCCTT-3′
Extension 5′-ACGCACTGTCCCTTGGGGTCC-3′
Rs6078871 5′-ACGTTGGATGCAGGAGGGCCAGTTCTCAT-3′
2 5′-ACGTTGGATGAAGACAAACAGAGGTCAGGC-3′
Extension 5′-AAACCGGAGGGTAGGGGCCAAAT-3′

[i] LRP5, low-density lipoprotein receptor-related protein 5; SNP, single-nucleotide polymorphism.

Multiplex PCR was performed in 5 µl volumes containing 0.1 units of HotStarTaq polymerase (Qiagen, Hilden, Germany), 10 ng whole-genome-amplified genomic DNA, 2.5 pmol of each PCR primer and 2.5 µmol deoxynucleotides (dNTP; Qiagen). Thermocycling was performed at 94°C for 15 min followed by 45 cycles at 94°C for 20 sec, 56°C for 30 sec, and 72°C for 1 min, and a final incubation at 72°C for 3 min. Unincorporated dNTPs were deactivated using 0.3 units of shrimp alkaline phosphatase (Sequenom) followed by primer extension using 5.4 pmol of each primer extension probe, 50 µmol of the appropriate ddNTP combination, and 0.5 units of iPLEX enzyme (Sequenom). The extension reactions were carried out at 94°C for 30 sec and then 94°C for 5 sec, followed by 5 cycles at 52°C for 5 sec and 80°C for 5 sec for a total of 40 cycles, and then 72°C for 3 min. A cation exchange resin was used to remove residual salt from the reactions. Purified primer extension reaction products were spotted onto a 384-well spectroCHIP using the MassARRAY Nanodispenser (Sequenom) and determined by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (Sequenom). Genotype calling was performed in real time with MassARRAY RT software version 3.0.0.4 (Sequenom) and analyzed by using the MassARRAY Typer software version 3.4 (Sequenom).

Statistical analysis

All statistical calculations were performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Hardy-Weinberg equilibrium (HWE) testing was carried out for all SNPs using the χ2 test, and P<0.001 was considered to indicate a statistically significant difference between cases and controls. The χ2 test was also used to assess frequencies of the selected allele and genotype between the cases and controls. The association between SNPs and NSCLC risk was evaluated by computing the odds ratio (OR) and 95% confidence interval (CI) from multivariate unconditional logistic regression analysis. Haploview software version 4.1 was used to analyze the association between haplotypes and the disease. All P-values were two-sided, and P<0.05 was considered to indicate a statistically significant difference.

Results

Study population description and clinical characteristics

A total of 500 patients (350 males and 150 females) and 500 healthy controls (259 males and 240 females; the gender information for one control subject was not available) of Chinese Han origin were included in this study. A total of 331 patients had adenocarcinoma (ADC), while 169 had squamous cell carcinoma (SCC). There were 280 male and 21 female patients who were smokers or former smokers, and 189 male and 14 female controls who were smokers or former smokers. All patients and controls were subjected to genotyping of 11 LRP5 tag SNPs (i.e., rs4930573, rs312009, rs312014, rs3781590, rs312015, rs491347, rs1784235, rs648438, rs3736228, rs624947 and rs607887). The selection was based on the following criteria: HapMap CHB, pairwise r2 ≥0.8, and MAF ≥0.1. The cases and controls were within the HWE for these 11 Tag SNPs, and the P-values are shown in Table II.

Table II.

Hardy-Weinberg equilibrium of LRP5 single-nucleotide polymorphisms between cases and controls.

Table II.

Hardy-Weinberg equilibrium of LRP5 single-nucleotide polymorphisms between cases and controls.

SNPsControlsMale controlsFemale controlsNSCLCsMale NSCLCsFemale NSCLCsADCsMale ADCsFemale ADCsSCCsMale SCCsFemale SCCs
Rs49305730.480.230.870.350.200.780.800.750.970.180.080.35
Rs3120090.150.720.010.590.590.890.400.330.960.690.630.85
Rs3120140.410.610.480.730.310.350.800.320.440.850.720.45
Rs37815900.300.170.660.040.140.160.200.590.190.100.120.51
Rs3120150.940.880.750.600.230.370.980.290.230.410.580.19
Rs4913470.170.280.290.760.200.120.480.060.200.640.830.35
Rs17842350.190.280.330.840.270.160.560.080.200.640.750.72
Rs6484380.470.640.590.150.140.740.630.940.590.040.020.51
Rs37362280.100.190.240.970.230.060.790.080.080.790.910.72
Rs6249470.730.810.440.040.030.700.160.100.830.130.160.51
Rs6078870.250.320.470.650.190.240.530.080.270.920.980.72

[i] LRP5, low-density lipoprotein receptor-related protein 5; SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma.

LRP5 polymorphisms in cases and controls

The allele frequencies of LRP5 SNPs in the cases and controls were analyzed. The frequency of the rs3736228 T allele was 18.9% and that of the C allele was 81.1% in the male NSCLC patients, whereas they were 23.9% and 76.1%, respectively, for the male controls (P=0.03). Logistic regression analysis revealed that the T allele is associated with a lower risk of developing NSCLC (OR=0.74; 95% CI, 0.56–0.67). In contrast, the frequency of rs3736228 was similar between NSCLC patients and controls and between female NSCLC patients and female controls (P>0.05). The differences in allele frequencies in the other 10 Tag SNPs (i.e., rs4930573, rs312009, rs312014, rs3781590, rs312015, rs491347, rs1784235, rs648438, rs624947 and rs607887) between cases and controls, male patients and male controls, as well as female patients and female controls were not statistically significant (Table III).

Table III.

Allele frequency of LRP5 single-nucleotide polymorphisms in non-small cell lung cancer patients and healthy controls.

Table III.

Allele frequency of LRP5 single-nucleotide polymorphisms in non-small cell lung cancer patients and healthy controls.

Gene alleleNSCLC n (%)Controls n (%)P-valueOR (95% CI)Male cases n (%)Male cases n (%)P-valueOR (95% CI)Female cases n (%)Female controls n (%)P-valueOR (95% CI)
Rs4930573 0.271.14 (0.91–1.43) 0.571.09 (0.81–1.46) 0.351.19 (0.81–1.73)
  C827 (82.7)808 (80.8) 579 (82.7)422 (81.5) 248 (82.7)384 (80.0)
  G173 (17.3)192 (19.2) 121 (17.3)96 (18.5) 52 (17.3)96 (20.0)
Rs312009 0.960.99 (90.81–1.22) 0.921.01 (0.78–1.32) 0.680.93 (0.66–1.31)
  T244 (24.4)245 (24.5) 176 (25.1)129 (24.9) 68 (22.7)115 (24.0)
  G756 (75.6)755 (75.5) 524 (74.9)389 (75.1) 232 (77.3)365 (76.0)
Rs312014 0.231.12 (0.94–1.33) 0.231.15 (0.92–1.44) 0.721.06 (0.79–1.41)
  C557 (55.7)530 (53.0) 393 (56.1)273 (52.7) 164 (54.7)256 (53.3)
  G443 (44.3)470 (47.0) 307 (43.9)245 (47.3) 136 (45.3)224 (46.7)
Rs3781590 1.001.00 (0.75–1.34) 0.211.29 (0.86–1.94) 0.360.81 (0.51–1.28)
  T101 (10.1)101 (10.1) 70 (10.0)41 (7.9) 31 (10.3)60 (12.5)
  C899 (89.9)899 (89.9) 630 (90.0)477 (92.1) 269 (89.7)420 (87.5)
Rs312015 0.960.99 (0.83–1.19) 0.921.01 (0.80–1.28) 0.880.98 (0.73–1.31)
  C398 (39.8)399 (39.9) 279 (39.9)205 (39.6) 119 (39.7)193 (40.2)
  G602 (60.2)601 (60.1) 421 (60.1)313 (60.4) 181 (60.3)287 (59.8)
Rs491347 0.401.10 (0.88–1.37) 0.141.23 (0.93–1.62) 0.861.04 (0.71–1.52)
  T810 (81.0)795 (79.5) 561 (80.1)397 (76.6) 249 (83.0)396 (82.5)
  C190 (19.0)205 (20.5) 139 (19.9)121 (23.4) 51 (17.0)84 (17.5)
Rs1784235 0.371.11 (0.89–1.38) 0.091.26 (0.96–1.67) 0.990.99 (0.68–1.46)
  T812 (81.2)796 (79.6) 564 (80.6)397 (76.6) 248 (82.7)397 (82.7)
  C188 (18.8)204 (20.4) 136 (19.4)121 (23.4) 52 (17.3)83 (17.3)
Rs648438 0.381.13 (0.85–1.51) 0.181.30 (0.89–1.89) 0.520.87 (0.56–1.34)
  T899 (89.9)887 (88.7) 638 (91.1)460 (88.8) 261 (87.0)425 (88.5)
  C101 (10.1)113 (11.3) 62 (8.9)58 (11.2) 39 (13.0)55 (11.5)
Rs3736228 0.160.85 (0.69–1.07) 0.181.30 (0.89–1.89) 0.930.98 (0.67–1.43)
  T185 (18.5)210 (21.0) 132 (18.9)124 (23.9) 53 (17.7)86 (17.9)
  C815 (81.5)790 (79.0) 568 (81.1)394 (76.1) 247 (82.3)394 (82.1)
Rs624947 0.791.03 (0.80–1.33) 0.250.82 (0.58–1.15) 0.171.34 (0.89–2.02)
  A863 (86.3)859 (85.9) 602 (86.0)457 (88.2) 261 (87.0)400 (83.3)
  G137 (13.7)141 (14.1) 98 (14.0)61 (11.8) 39 (13.0)80 (16.7)
Rs607887 0.270.89 (0.72–1.09) 0.080.79 (0.61–1.03) 0.991.00 (0.71–1.42)
  T227 (22.7)248 (24.8) 160 (22.9)141 (27.2) 67 (22.3)107 (22.3)
  C773 (77.3)752 (75.2) 540 (77.1)377 (72.8) 233 (77.7)373 (77.7)

[i] LRP5, low-density lipoprotein receptor-related protein 5; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval.

The genotype distribution of LRP5 SNPs was also analyzed. For rs3736228 polymorphisms, logistic regression analysis revealed that the C/C major allele homozygote was associated with an increased risk of NSCLC in the male population (C/C frequencies were 64.9% and 56.4% in male NSCLC patients and controls, respectively; OR=1.43; 95% CI, 0.33–1.99; P=0.03; Table IV). For rs64843 polymorphisms, the T/T major allele homozygote had a 1.77-fold greater risk of developing SCC compared with the C/C and C/T genotypes (95% CI, 1.02–3.04; P=0.04). The T/T frequencies were 87.0% and 79.2% in male SCC patients and controls, respectively (Table V).

Table IV.

Genotypes of LRP5 single-nucleotide polymorphisms in non-small cell lung cancer patients and controls.

Table IV.

Genotypes of LRP5 single-nucleotide polymorphisms in non-small cell lung cancer patients and controls.

GenotypeNSCLC n=500 (%)Controls n=500 (%)P-valueOR (95% CI)Male NSCLCs n=350 (%)Male controls n=259 (%)P-valueOR (95% CI)Female NSCLCs n=150 (%)Female controls n=240 (%)P-valueOR (95% CI)
Rs4930573
  CC339 (67.8)324 (64.8) 1 (Reference)236 (67.4)169 (65.3) 1 (Reference)103 (68.7)154 (64.2) 1 (Reference)
  GG12 (2.4)16 (3.2) 7 (2.0)6 (2.3) 5 (3.3)10 (4.2)
  CG149 (29.8)160 (32.0)0.52107 (30.6)84 (32.4)0.8442 (28.0)76 (31.7)0.65
  CG+GG161 (32.2)176 (35.2)0.320.87 (0.67–1.14)114 (32.6)90 (34.7)0.530.91 (0.65–1.27)47 (31.3)86 (35.8)0.360.82 (0.53–1.26)
Rs312009
  CC288 (57.6)291 (58.2) 1 (Reference)198 (56.6)145 (56.0) 1 (Reference)90 (60.0)146 (60.8) 1 (Reference)
  TT32 (6.4)36 (7.2) 24 (6.9)15 (5.8) 8 (5.3)21 (8.7)
  CT180 (36.0)173 (34.6)0.82128 (36.5)99 (38.2)0.8352 (34.7)73 (30.5)0.37
  TT+CT212 (42.4)209 (41.8)0.850.98 (0.76–1.25)152 (43.4)114 (44.0)0.891.02 (0.74–1.42)60 (40.0)94 (39.2)0.360.82 (0.53–1.26)
Rs312014
  CC157 (31.4)145 (29.0) 1 (Reference)115 (32.9)74 (28.6) 1 (Reference)42 (28.0)71 (29.6) 1 (Reference)
  CG243 (48.6)240 (48.0) 163 (46.6)125 (48.2) 80 (53.3)114 (47.5)
  GG100 (20.0)115 (23.0)0.4672 (20.5)60 (23.2)0.4928 (18.7)55 (22.9)0.47
  GG+CG343 (68.6)355 (71.0)0.411.12 (0.86–1.47)235 (67.1)185 (71.4)0.261.22 (0.86–1.74)108 (72.0)169 (70.4)0.740.93 (0.59–1.45)
Rs3781590
  CC400 (80.0)402 (80.4) 1 (Reference)281 (80.3)218 (84.2) 1 (Reference)119 (79.3)183 (76.2) 1 (Reference)
  TT1 (0.2)3 (0.6) 1 (0.3)0 (0.0) 0 (0.0)3 (1.3)
  CT99 (19.8)95 (19.0)0.5868 (19.4)41 (15.8)0.3531 (20.7)54 (22.5)0.34
  TT+CT100 (20.0)98 (19.6)0.870.98 (0.71–1.33)69 (19.7)41 (15.8)0.220.77 (0.50–1.17)31 (20.7)57 (23.8)0.481.20 (0.73–1.96)
Rsa312015
  GG184 (36.8)181 (36.2) 1 (Reference)132 (37.7)94 (36.3) 1 (Reference)52 (34.7)87 (36.2) 1 (Reference)
  CG234 (46.8)239 (47.8) 157 (44.9)125 (48.3) 77 (51.3)113 (47.1)
  CC82 (16.4)80 (16.0)0.9561 (17.4)40 (15.4)0.6721 (14.0)40 (16.7)0.66
  CC+CG316 (63.2)319 (63.8)0.841.03 (0.79–1.33)218 (62.3)165 (63.7)0.721.06 (0.76–1.48)98 (65.3)153 (63.7)0.750.93 (0.64–1.50)
Rs491347
  TT327 (65.4)311 (62.2) 1 (Reference)221 (63.1)149 (57.5) 1 (Reference)106 (70.7)161 (67.1) 1 (Reference)
  CC17 (3.4)16 (3.2) 10 (2.9)11 (4.2) 7 (4.6)5 (2.1)
  CT156 (31.2)173 (34.6)0.52119 (034.0)99 (38.2)0.3137 (24.7)74 (30.8)0.18
  CC+CT173 (34.6)189 (37.8)0.291.15 (0.89–1.49)129 (36.9)110 (42.5)0.161.27 (0.91–1.76)44 (0.293)79 (32.9)0.461.18 (0.77–1.85)
Rs1784235
  TT329 (65.8)312 (62.4) 1 (Reference)224 (64.0)149 (57.5) 1 (Reference)105 (70.0)162 (67.5) 1 (Reference)
  CC17 (3.4)16 (3.2) 10 (2.9)11 (4.2) 7 (4.7)5 (2.1)
  CT154 (30.8)172 (34.4)0.48116 (33.1)99 (38.2)0.2338 (25.3)73 (30.4)0.23
  CC+CT171 (34.2)188 (37.6)0.261.16 (0.90–1.50)126 (36.0)110 (42.5)0.111.31 (0.94–1.82)45 (30.0)78 (32.5)0.611.12 (0.72–1.75)
Rs648438
  TT407 (81.4)395 (79.0) 1 (Reference)293 (83.7)205 (79.2) 1 (Reference)114 (76.0)189 (78.7) 1 (Reference)
  CC8 (1.6)8 (1.6) 5 (1.4)4 (1.5) 3 (2.0)4 (1.7)
  CT85 (17.0)97 (19.4)0.6252 (14.9)50 (19.3)0.3433 (22.0)47 (19.6)0.81
  CC+CT93 (18.6)105 (21.0)0.341.16 (0.85–1.59)57 (16.3)54 (20.8)0.151.35 (0.90–2.06)36 (24.0)51 (21.3)0.530.85 (0.53–1.39)
Rs3736228
  CC332 (66.4)306 (61.2) 1 (Reference)227 (64.9)146 (56.4) 1 (Reference)105 (70.0)159 (66.2) 1 (Reference)
  TT17 (3.4)16 (3.2) 9 (2.6)11 (4.2) 8 (5.3)5 (2.1)
  CT151 (30.2)178 (35.6)0.19114 (32.6)102 (39.4)0.0837 (24.7)76 (31.7)0.10
  TT+CT168 (33.6)194 (38.8)0.091.25 (0.97–1.62)123 (35.1)113 (43.6)0.031.43 (0.03–1.99)45 (30.0)81 (33.8)0.441.19 (0.77–1.85)
Rs624947
  AA367 (73.4)368 (73.6) 1 (Reference)254 (72.6)202 (78.0) 1 (Reference)113 (75.3)165 (68.8) 1 (Reference)
  AG129 (25.8)123 (24.6) 94 (26.9)53 (20.5) 35 (23.3)70 (29.2)
  GG4 (0.8)9 (1.8)0.362 (0.6)4 (1.5)0.102 (1.3)5 (2.1)0.36
  AG+GG133 (26.6)132 (26.4)0.940.99 (0.75–1.31)96 (27.4)57 (22.0)0.130.75 (0.51–1.09)37 (24.7)75 (31.3)0.161.39 (0.88–2.20)
Rs607887
  CC297 (59.4)278 (55.6) 1 (Reference)204 (58.3)134 (51.7) 1 (Reference)93 (62.0)143 (59.6) 1 (Reference)
  TT24 (4.8)26 (5.2) 14 (4.0)16 (6.2) 10 (6.7)10 (4.2)
  CT179 (0.358)196 (39.2)0.48132 (37.7)109 (42.1)0.1947 (31.3)87 (36.2)0.39
  TT+CT203 (40.6)222 (44.4)0.221.17 (0.91–1.50)146 (41.7)125 (48.3)0.111.30 (0.94–1.80)57 (38.0)97 (40.4)0.631.11 (0.73–1.68)

[i] LRP5, low-density lipoprotein receptor-related protein 5; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval.

Table V.

Genotypes of LRP5 single-nucleotide polymorphisms in squamous cell carcinoma patients and controls.

Table V.

Genotypes of LRP5 single-nucleotide polymorphisms in squamous cell carcinoma patients and controls.

GenotypeSCC n=169 (%)Controls n=500 (%)P-valueOR (95% CI)Male SCCs n=161 (%)Male controls n=259 (%)P-valueOR (95% CI)Female SCCs n=8 (%)Female controls n=240 (%)P-valueOR (95% CI)
Rs4930573
  CC117 (69.2)324 (64.8) 1 (Reference)112 (69.6)169 (65.3) 1 (Reference)5 (62.5)154 (64.2) 1 (Reference)
  GG2 (1.2)16 (3.2) 1 (0.6)6 (2.3) 1 (12.5)10 (4.2)
  CG50 (29.6)160 (32.0)0.2848 (29.8)84 (32.4)0.332 (25.0)76 (31.6)0.52
  CG+GG52 (30.8)176 (35.2)0.290.82 (0.56–1.19)49 (30.4)90 (34.7)0.360.82 (0.54–1.25)3 (37.5)86 (35.8)0.921.07 (0.25–4.61)
Rs312009
  CC103 (60.9)291 (0.582) 1 (Reference)96 (59.6)145 (56.0) 1 (Reference)7 (87.5)146 (60.8) 1 (Reference)
  TT7 (4.1)36 (0.072) 7 (4.4)15 (5.8) 0 (0.0)21 (8.7)
  CT59 (34.9)173 (0.346)0.3758 (36.0)99 (38.2)0.691 (12.5)73 (30.4)0.30
  TT+CT66 (39.1)209 (0.418)0.531.12 (0.79–1.60)65 (40.4)114 (44.0)0.461.16 (0.78–1.73)1 (12.5)94 (39.2)0.134.51 (0.55–37.22)
Rs312014
  CC58 (34.3)145 (29.0) 1 (Reference)56 (34.8)74 (28.6) 1 (Reference)2 (25.0)71 (29.6) 1(Reference)
  CG81 (47.9)240 (48.0) 76 (47.2)125 (48.3) 5 (62.5)114 (47.5)
  GG30 (17.8)115 (23.0)0.2529 (18.0)60 (23.2)0.291 (12.5)55 (22.9)0.67
  GG+CG111 (65.7)355 (71.0)0.191.28 (0.88–1.86)105 (65.2)185 (71.4)0.181.33 (0.882.03)6 (75.0)169 (70.4)0.781.26 (0.25–6.40)
Rs3781590
  CC131 (77.5)402 (80.4) 1 (Reference)126 (78.3)218 (84.2) 1 (Reference)5 (62.5)183 (76.2) 1 (Reference)
  TT0 (0.0)3 (0.6) 0 (0.0)0 (0.0) 0 (0.0)3 (1.3)
  CT38 (22.5)95 (19.0)0.3835 (21.7)41(15.8)0.133 (37.5)54 (22.4)0.59
  TT+CT38 (22.5)98 (19.6)0.420.84 (0.55–1.28)35 (21.7)41 (15.8)0.130.68 (0.41–1.12)3 (37.5)57 (23.7)0.370.52 (0.12–2.24)
Rsa312015
  GG69 (40.8)181 (36.2) 1 (Reference)65 (40.4)94 (36.3) 1 (Reference)4 (50.0)87 (36.2) 1 (Reference)
  CC26 (15.4)80 (16.0) 24 (14.9)40 (15.4) 2 (25.0)40 (16.7)
  CG74 (43.8)239 (47.8)0.5572 (44.7)125 (48.3)0.702 (25.0)113 (47.1)0.47
  CC+CG100 (59.2)319 (63.8)0.281.21 (0.85–1.74)96 (59.6)165 (63.7)0.401.19 (0.79–1.78)4 (0.500)153 (63.7)0.431.76 (0.43–7.21)
Rs491347
  TT112 (66.3)311 (62.2) 1 (Reference)107 (66.5)149 (57.5) 1 (Reference)5 (62.5)161 (67.1) 1 (Reference)
  CC7 (4.1)16 (3.2) 6 (3.7)11 (4.3) 1 (12.5)5 (2.1)
  CT50 (29.6)173 (34.6)0.4548 (29.8)99 (38.2)0.192 (25.0)74 (30.8)0.17
  CC+CT57 (33.7)189 (37.8)0.341.19 (0.83–1.72)54 (33.5)110 (42.5)0.071.46 (0.97–2.20)3 (37.5)79 (32.9)0.790.82 (0.19–3.51)
Rs1784235
  TT112 (66.3)312 (62.4) 1 (Reference)108 (67.1)149 (57.5) 1 (Reference)4 (50.0)162 (67.5)   1 (Reference)
  CC7 (4.1)16 (3.2) 6 (3.7)11 (4.2) 1 (12.5)5 (2.1)
  CT50 (29.6)172 (34.4)0.4747 (29.2)99 (38.2)0.143 (37.5)73 (30.4)0.14
  CC+CT57 (33.7)188 (37.6)0.371.18 (0.82–1.71)53 (32.9)110 (42.5)0.051.50 (1.00–2.27)4 (50.0)78 (32.5)0.300.48 (0.12–1.98)
Rs648438
  TT145 (85.8)395 (79.0) 1 (Reference)140 (87.0)205 (79.2) 1 (Reference)5 (62.5)189 (78.7) 1 (Reference)
  CC3 (1.8)8 (1.6) 3 (1.9)4 (1.5) 0 (0.0)4 (1.7)
  CT21 (12.4)97 (19.4)0.1218 (11.1)50 (19.3)0.093 (37.5)47 (19.6)0.44
  CC+CT24 (14.2)105 (21.0)0.051.61 (0.9–2.60)21 (13.0)54 (20.8)0.041.77 (1.02–3.04)3 (37.5)51 (21.3)0.270.45 (0.10–1.95)
Rs3736228
  CC110 (65.1)306 (61.2) 1 (Reference)106 (65.8)146 (56.4) 1 (Reference)4 (50.0)159 (66.2) 1 (Reference)
  TT7 (4.1)16 (3.2) 6 (3.7)11 (4.2) 1 (12.5)5 (2.1)
  CT52 (30.8)178 (35.6)0.4749 (30.5)102 (39.4)0.153 (37.5)76 (31.7)0.14
  TT+CT59 (34.9)194 (38.8)0.361.18 (0.82–1.70)55 (34.2)113 (43.6)0.051.49 (0.99–2.24)4 (50.0)81 (33.8)0.340.51 (0.12–2.09)
Rs624947
  AA122 (72.2)368 (73.6) 1 (Reference)117 (72.7)202 (78.0) 1 (Reference)5 (62.5)165 (68.8) 1 (Reference)
  AG46 (27.2)123 (24.6) 43 (26.7)53 (20.5) 3 (37.5)70 (29.2)
  GG1 (0.6)9 (1.8)0.451 (0.6)4 (1.5)0.250 (0.0)5 (2.1)0.82
  AG+GG47 (27.8)132 (26.4)0.720.93 (0.63–1.38)44 (27.3)57 (22.0)0.210.75 (0.48–1.18)3 (37.5)75 (31.3)0.710.76 (0.18–3.25)
Rs607887
  CC101 (59.8)278 (55.6) 1 (Reference)97 (60.2)134 (51.7) 1 (Reference)4 (50.0)143 (59.6) 1 (Reference)
  TT9 (5.3)26 (5.2) 8 (5.0)16 (6.2) 1 (12.5)10 (4.2)
  CT59 (34.9)196 (39.2)0.6156 (34.8)109 (42.1)0.233 (37.5)87 (36.2)0.51
  TT+CT68 (40.2)222 (44.4)0.35 1.19(0.83–1.69)64 (39.8)125 (48.3)0.091.41 (0.95–2.11)4 (50.0)97 (40.4)0.590.68 (0.17–2.78)

[i] LRP5, low-density lipoprotein receptor-related protein 5; SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval.

Haploview software identified two blocks among NSCLCs, ADCs and controls, and male NSCLCs, male ADCs and male controls: the haplotypes were CG, TC and CC in Block 1 (the length of one block was 6 kb, including rs312009 and 3120015), and TTC, CCT and TTT in Block 2 (the length of the other block was 27 kb, including rs491347, rs1784235 and rs607887). Two blocks were identified among female NSCLCs, female ADCs and female controls: the haplotypes were CG, TC and CC in Block 1 (the length of one block was 6 kb, including rs312009 and 3120015), and TTCC, CCTT, TTTC and TTTT in Block 3 (the length of the other block was 31 kb, including rs491347, rs1784235, rs607887 and rs3736228). Two blocks were identified among SCCs and controls, and male SCCs and male controls: the haplotypes were CGC, TCG, CCG and CGG in Block 4 (the length of one block was 7 kb, including rs312009, rs3120014 and rs3120015), and TTC, CCT and TTT in Block 2 (the length of the other block was 27 kb, including rs491347, rs1784235 and rs607887). Two blocks were identified among female SCCs and female controls: the haplotypes were CGC, TCG, CCG, CGG and CCC in Block 4 (the length of one block was 7 kb, including rs312009, rs3120015 and rs3120014), and TTCC, CCTT, TTTC and TTTT in Block 3 (the length of the other block was 31 kb, including rs491347, rs1784235, rs607887 and rs3736228). Among these results, only the frequency of haplotypes rs312009/rs3120015/rs3120014 CCC were significantly higher in female SCC patients vs. female controls (0.064 vs. 0.009; P=0.04; Table VI).

Table VI.

Haplotype distribution and formation between patients and controls for association of haplotype blocks with non-small cell lung cancer risk.

Table VI.

Haplotype distribution and formation between patients and controls for association of haplotype blocks with non-small cell lung cancer risk.

Frequency (%)
BlockLociCases/controlsHaplotypeCasesControlsP-value
Block 1rs312009 and 3120015NSCLC patientsCG60.260.00.93
ControlsTC24.424.50.98
CC15.415.50.94
Male NSCLC patientsCG60.160.30.96
Male controlsTC25.124.80.89
CC14.714.90.92
ADC patientsCG58.960.00.65
ControlsTC25.824.40.52
CC15.315.50.88
Male ADC patientsCG57.960.20.49
Male controlsTC27.524.70.34
CC14.614.90.89
Female NSCLC patientsCG60.359.80.88
Female controlsTC22.724.00.68
CC17.016.20.78
Female ADC patientsCG60.259.80.91
Female controlsTC23.624.00.91
CC16.216.20.98
Block 2rs491347, rs1784235, and rs607887NSCLC patientsTTC76.674.60.28
ControlsCCT18.319.90.37
TTT4.34.90.53
Male NSCLC patientsTTC76.172.20.12
Male controlsCCT18.822.80.09
TTT4.04.50.70
ADC patientsTTC76.674.60.36
ControlsCCT18.319.90.41
TTT4.44.90.62
Male ADC patientsTTC75.672.20.25
Male controlsCCT19.522.70.25
TTT3.54.50.46
SCC patientsTTC76.874.60.42
ControlsCCT18.419.90.56
TTT4.24.90.58
Male SCC patientsTTC77.072.20.12
Male controlsCCT18.022.80.10
TTT4.44.50.95
Block 3rs491347, rs1784235, rs607887 and rs3736228Female NSCLC patientsTTCC77.677.10.85
Female controlsCCTT16.316.70.90
TTTC4.04.20.92
TTTT1.01.30.75
Female ADC patientsTTCC78.177.10.73
Female controlsCCTT15.816.70.77
TTTC4.34.20.96
TTTT1.11.30.81
Female SCC patientsTTCC68.777.10.43
Female controlsCCTT25.016.70.38
TTTC0.04.20.40
TTTT0.01.30.65
Block 4rs312009, rs3120014 and rs3120015SCC patientsCGC57.652.40.09
ControlsTCG21.624.40.29
CCG15.014.90.94
CGG5.17.70.11
Male SCC patientsCGC58.052.30.10
Male controlsTCG22.324.70.44
CCG14.624.50.97
CGG4.77.90.07
Female SCC patientsCGC49.952.40.84
Female controlsTCG6.224.00.10
CCG24.915.30.30
CGG12.67.40.45
CCC6.40.90.04

[i] NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma.

Discussion

In the current study, we investigated the association between LRP5 polymorphisms and NSCLC risk. We observed that LRP5 rs3736228 and rs648438 polymorphisms were strongly associated with the risk of NSCLC and lung SCC. Based on this finding, rs3736228 and rs648438 are two novel susceptibility loci that were associated with an increased risk of developing NSCLC in this Chinese male population. To the best of our knowledge, this is the first study describing the association of rs3736228 and rs648438 SNPs with NSCLC risk in humans.

LRP5 is a co-receptor for canonical Wnt-mediated signaling (8). In transgenic mice, loss of LRP5 expression markedly reduces the formation of mammary tumors (19). In osteosarcoma tissue, the expression of LRP5 mRNA has been correlated with metastatic disease and a poorer event-free survival in patients (20). Moreover, dominant-negative LRP5 inhibits the growth and metastasis of osteosarcoma in animal models and reduces the expression of cancer cell invasion-associated markers (including N-cadherin, Snail and matrix metalloprotease-2) (21). Thus, these data suggest that LRP5 may function as an oncogene. In the current study, we analyzed rs3736228 and rs648438 SNPs, which are localized in the region of the LRP5 gene on 11q13.2. A previous study has revealed that chromosome 11q is a susceptibility region for NSCLC (17). The present study confirmed these data, suggesting that LRP5 may be a candidate susceptibility gene for NSCLC.

By selecting the Tag SNPs across the LRP5 gene from the HapMap CHB database using the approach of Carlson et al (22), the criteria for the selection of Tag SNPs enabled us to maximize the power to detect SNPs (the statistical power of our study was >80%); thus, 11 SNPs were selected and two SNPs (rs3736228 and rs648438) were associated with NSCLC risk, which indicated that this methodology is useful in identifying susceptibility loci for NSCLC.

Furthermore, rs3736228 is a SNP in LRP5, which is also known as Ala1330Val or A1330V; the more common C allele encodes Ala, while the rarer T allele encodes Val, and the latter is the risk allele. In the LRP5 gene, a C→T transition at rs3736228 results in a substitution of Val for Ala, and this transition significantly decreases the response to canonical Wnt signaling (23). Published data have identified that polymorphisms of rs3736228 are associated with a decrease in bone mineral density in postmenopausal Maya-mestizo females (24), Mexican females (25), healthy fertile French females (26), Japanese male workers (27), Chinese patients (28), and Chinese patients with osteoporosis (29,30). However, to date, there are no studies describing an association between rs3736228 polymorphisms and lung cancer. In the present study, we noted that individuals with the rs3736228 C allele had a lower risk of developing NSCLC compared with those carrying the T allele. Compared with the C/C homozygote, other genotypes (C/T and T/T) had a greater risk of developing NSCLC in the male population, but not in the female population. The reason for this discrepancy is not clear, but it may be due to the fact that a high percentage of males in China smoke cigarettes (over 90% of the males in our study were smokers, compared with less than 10% of the females). Polymorphisms of rs3736228 have a combined effect with cigarette smoking; people that smoke cigarettes (current and former smokers) with rs3736228 polymorphisms have a 4.1-fold greater (95% CI, 1.6–10.2) risk of having metabolic syndrome (31). In addition, tobacco smokers have a much greater chance of developing lung cancer (32). Our results suggest that, among smokers, East Asian males with the rs3736228 SNP have a higher susceptibility to develop NSCLC.

Another potential susceptibility locus for NSLCL risk was determined to be rs648438 in our current study. Rs648438 is located in the intron region of LRP5, which has not been reported to be associated with any diseases. The present study reveals that an rs648438 polymorphism was associated with lung SCC development in males carrying at least one C allele (C/C and C/T) compared with those carrying the T/T homozygote. In this study, there were 549 male smokers among the 609 male subjects (including cases and controls), whereas there were only 35 female smokers among the 490 female subjects. Tobacco smoking is a strong risk factor for all types of lung cancer, and among male smokers SCC is the predominant subtype: the greater the amount smoked, the greater the proportion of SCC cases relative to ADC cases (18). The current data indicated that among smokers, East Asian males with rs648438 had a higher susceptibility of developing SCC.

Although these two potential susceptibility loci are novel and were associated with an increased risk of NSCLC, the present study does have certain limitations, For example, our eligible population was living in Zhejiang province, China. Gene polymorphisms are known to be influenced by ethnicity, location and environment. Therefore, further investigation is required to confirm our data using other ethnicities.

Acknowledgements

The authors thank Xiaohong Xu and Yejiang Bao for their assistance in control screening. They also thank Hailong Liu for his technical support. The abstract of this paper was previously published at the 6th Asian Oncology Summit and 10th Annual Conference of the Organisation for Oncology and Translational Research, 11 April 2014–13 April 2014: www.ejcancer.com/article/S0959-8049(14)00306-2/abstract.

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI

3 

Schwartz AG, Wenzlaff AS, Bock CH, Ruterbusch JJ, Chen W, Cote ML, Artis AS, Van Dyke AL, Land SJ, Harris CC, et al: Admixture mapping of lung cancer in 1812 African-Americans. Carcinogenesis. 32:312–317. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Alberg AJ and Samet JM: Epidemiology of lung cancerMurray & Nadel's Textbook of Respiratory Medicine. Mason RJ, et al: 5th edition. Saunders Elsevier; Amsterdam: pp. 927–939. 2010

5 

Matakidou A, Eisen T and Houlston RS: Systematic review of the relationship between family history and lung cancer risk. Br J Cancer. 93:825–833. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, SzeszeniaDabrowska N, Lissowska J, Rudnai P, et al: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 452:633–637. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Zhang Y, Hua S, Zhang A, Kong X, Jiang C, Deng D and Wenlong B: Association between polymorphisms in COMT, PLCH1, and CYP17A1, and non-small-cell lung cancer risk in Chinese nonsmokers. Clin Lung Cancer. 14:45–49. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, SaintJeannet JP and He X: LDL-receptor-related proteins in Wnt signal transduction. Nature. 407:530–535. 2000. View Article : Google Scholar : PubMed/NCBI

9 

Dieckmann M, Dietrich MF and Herz J: Lipoprotein receptors - an evolutionarily ancient multifunctional receptor family. Biol Chem. 391:1341–1363. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Joiner DM, Ke J, Zhong Z, Xu HE and Williams BO: LRP5 and LRP6 in development and disease. Trends Endocrinol Metab. 24:31–39. 2013. View Article : Google Scholar : PubMed/NCBI

11 

MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Lee EH, Chari R, Lam A, Ng RT, Yee J, English J, Evans KG, Macaulay C, Lam S and Lam WL: Disruption of the non-canonical WNT pathway in lung squamous cell carcinoma. Clin Med Oncol. 2008.169–179. 2008.PubMed/NCBI

13 

Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Staal FJ and Clevers HC: WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol. 5:21–30. 2005. View Article : Google Scholar : PubMed/NCBI

15 

El Wakil A and Lalli E: The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol. 332:32–37. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Liu CX, Musco S, Lisitsina NM, Forgacs E, Minna JD and Lisitsyn NA: LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 60:1961–1967. 2000.PubMed/NCBI

17 

Berrieman HK, Ashman JN, Cowen ME, Greenman J, Lind MJ and Cawkwell L: Chromosomal analysis of non-small-cell lung cancer by multicolour fluorescent in situ hybridisation. Br J Cancer. 90:900–905. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, Olsson A, Ahrens W, Gross IM, Brüske I, et al: Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 131:1210–1219. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Lindvall C, Evans NC, Zylstra CR, Li Y, Alexander CM and Williams BO: The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem. 281:35081–35087. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA and Gorlick R: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer. 109:106–111. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Guo Y, Rubin EM, Xie J, Zi X and Hoang BH: Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res. 466:2039–2045. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L and Nickerson DA: Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 74:106–120. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Kiel DP, Ferrari SL, Cupples LA, Karasik D, Manen D, Imamovic A, Herbert AG and Dupuis J: Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men. Bone. 40:587–596. 2007. View Article : Google Scholar : PubMed/NCBI

24 

CantoCetina T, Polanco Reyes L, González Herrera L, Rojano-Mejía D, Coral-Vázquez RM, Coronel A and Canto P: Polymorphism of LRP5, but not of TNFRSF11B, is associated with a decrease in bone mineral density in postmenopausal maya-mestizo women. Am J Hum Biol. 25:713–718. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Falcón-Ramírez E, Casas-Avila L, Cerda-Flores RM, Castro-Hernández C, Rubio-Lightbourn J, Velázquez-Cruz R, Diez-G P, Peñaloza-Espinosa R and Valdés-Flores M: Association of LRP5 haplotypes with osteoporosis in Mexican women. Mol Biol Rep. 40:2705–2710. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Massart F, Marini F, Bianchi G, Minisola S, Luisetto G, Pirazzoli A, Salvi S, Micheli D, Miccoli M, Baggiani A, et al: Genetic predictors of skeletal outcomes in healthy fertile women: the Bonturno study. Joint Bone Spine. 80:414–419. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Funakoshi Y, Omori H, Yada H and Katoh T: A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene and bone mineral density in Japanese male workers. Environ Health Prev Med. 16:106–112. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Jiang XY, Chen Y, Xu L, Li X, Cao FF, Li L, Lu M, Jin L and Wang XF: Association of LPR5 polymorphism with bone mass density and cholesterol level in population of Chinese Han. Exp Clin Endocrinol Diabetes. 118:388–391. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Zhang YP, Deng FY, Chen Y, Pei YF, Fang Y, Guo YF, Guo X, Liu XG, Zhou Q, Liu YJ and Deng HW: Replication study of candidate genes/loci associated with osteoporosis based on genome-wide screening. Osteoporos Int. 21:785–795. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Jiang XY, Chen HH, Cao FF, Li L, Lin RY, Wen H, Jin L and Wang XF: A polymorphism near osteoprotegerin gene confer risk of obesity in Uyghurs. Endocrine. 37:383–388. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Yang CW, Li CI, Liu CS, Bau DT, Lin CH, Lin WY, Li TC and Lin CC: The joint effect of cigarette smoking and polymorphisms on LRP5, LEPR, near MC4R and SH2B1 genes on metabolic syndrome susceptibility in Taiwan. Mol Biol Rep. 40:525–533. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Frusch N, Bosquée L and Louis R: Lung cancer. Epidemiology and etiologic factors. Rev Med Liege. 62:548–553. 2007.(In French). PubMed/NCBI

Related Articles

Journal Cover

October-2016
Volume 12 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Zhang Y, Fang M, Bao W and Deng D: Two novel susceptibility loci for non‑small cell lung cancer map to low‑density lipoprotein receptor‑related protein 5. Oncol Lett 12: 2307-2318, 2016
APA
Wang, Y., Zhang, Y., Fang, M., Bao, W., & Deng, D. (2016). Two novel susceptibility loci for non‑small cell lung cancer map to low‑density lipoprotein receptor‑related protein 5. Oncology Letters, 12, 2307-2318. https://doi.org/10.3892/ol.2016.4954
MLA
Wang, Y., Zhang, Y., Fang, M., Bao, W., Deng, D."Two novel susceptibility loci for non‑small cell lung cancer map to low‑density lipoprotein receptor‑related protein 5". Oncology Letters 12.4 (2016): 2307-2318.
Chicago
Wang, Y., Zhang, Y., Fang, M., Bao, W., Deng, D."Two novel susceptibility loci for non‑small cell lung cancer map to low‑density lipoprotein receptor‑related protein 5". Oncology Letters 12, no. 4 (2016): 2307-2318. https://doi.org/10.3892/ol.2016.4954